疑难配血病例输血策略研究及输血疗效分析

官笑羽 ,  康凯 ,  李顺林 ,  李族军 ,  章容 ,  吴迪 ,  李玲

中国输血杂志 ›› 2026, Vol. 39 ›› Issue (9) : 1237 -1245.

PDF (1894KB)
中国输血杂志 ›› 2026, Vol. 39 ›› Issue (9) : 1237 -1245. DOI: 10.13303/j.cjbt.issn.1004-549x.2026.09.011
论著

疑难配血病例输血策略研究及输血疗效分析

作者信息 +

Transfusion strategies and efficacy analysis in patients with difficult crossmatching

Author information +
文章历史 +
PDF (1938K)

摘要

目的 分析疑难配血病例的原因构成及红细胞血型抗体分布特征,探讨基于血清学异常类型的相容性输血策略,并评价红细胞输注疗效及输血前后胆红素变化。方法 回顾性分析 2024 年 1 月至 2025 年 12 月本院输血科处理的疑难配血病例。 符合疑难配血判定标准且资料完整者纳入疑难配血原因及抗体分布分析;完成红细胞输注且具有完整输血前及输血后 24 h 内 Hb 资料者纳入探索性输血疗效亚组分析;其中具有与该次输血事件相对应的输血前后总胆红素和间接胆红素资料者纳入胆红素分析。 根据输血前主要血清学异常表现及实际相容性输血处理路径,将该探索性亚组病例分为同种抗体相关疑难配血组、自身抗体或自身抗体合并同种抗体相关疑难配血组、ABO 血型鉴定异常相关疑难配血组。 比较各组输血前后 Hb 水平、每单位红细胞输注后 Hb 提升量及输血前后胆红素变化值。结果 共 322 例配血病例符合疑难配血判定标准,其中 287 例纳入原因及抗体分布分析。 同种抗体相关疑难配血 183 例(63. 76%),ABO 正反定型不符相关 54 例(18. 82%),自身抗体相关 44 例(15. 33%),抗 CD38 单克隆抗体药物干扰 6 例(2. 09%)。 在 183 例同种抗体相关病例中,79 例仅检出单一同种抗体,其中 Rh 血型系统抗体占 49. 37%(39/ 79);单一同种抗体中特异性抗-E 检出最多,为 35 例(44. 30%),其次为抗-M 19 例(24. 05%) 和抗-Lea 13 例(16. 46%)。 109 例纳入探索性输血疗效亚组分析,其中同种抗体相关疑难配血组 76 例,自身抗体或自身抗体合并同种抗体相关疑难配血组 17 例,ABO 血型鉴定异常相关疑难配血组 16 例。 纳入病例与未纳入病例的性别构成及既往输血史存在差异。 三组输血后 Hb 均较输血前升高,差异均有统计学意义(P<0. 05);三组每单位红细胞输注后 Hb 提升量比较差异无统计学意义(P= 0. 086)。 73 例具有与输血事件对应的输血前后总胆红素及间接胆红素检测资料,三组总胆红素变化值比较差异无统计学意义(P= 0. 864),间接胆红素变化值比较差异亦无统计学意义(P= 0. 914)。结论 同种抗体相关因素是本研究疑难配血的主要原因,单一同种抗体中以 Rh 血型系统抗体尤其抗-E 较为常见。 在本研究纳入的探索性疗效亚组中,依据疑难配血原因、抗体特异性及交叉配血结果实施个体化相容性输血后,三组患者输血后 Hb 总体均较输血前升高。 在本研究观察范围内,不同疑难配血类型患者输血后胆红素变化幅度未见明显差异。

Abstract

Objective To analyze the etiologic distribution of difficult crossmatching and the characteristics of red blood cell antibodies, to summarize compatible transfusion strategies based on serological abnormalities, and to evaluate red blood cell transfusion efficacy and changes in bilirubin levels before and after transfusion. Methods A retrospective analysis was conducted on difficult crossmatching cases handled by the Department of Blood Transfusion of our hospital from January 2024 to December 2025. Cases that met the criteria for difficult crossmatching determination and had complete data were included in the analysis of the causes and antibody distribution. Patients who completed red blood cell transfusion and had complete hemoglobin (Hb) data before and within 24 hours after transfusion were included in the exploratory subgroup analysis of transfusion efficacy; among them, those who also had total bilirubin and indirect bilirubin data before and after the corresponding transfusion event were included in the bilirubin analysis. According to the main serological abnormal manifestations before transfusion and the actual compatible transfusion management pathways, the cases included in the exploratory subgroup analysis were divided into three groups:the alloantibody-related difficult crossmatching group, the autoantibody-related or autoantibody combined with alloantibody-related difficult crossmatching group, and the ABO blood group identification abnormality-related difficult crossmatching group. The Hb levels before and after transfusion, the Hb increase after transfusion of each unit of red blood cells, and the changes in bilirubin levels before and after transfusion were compared among the groups. Results A total of 322 difficult crossmatching cases met the predefined criteria, of which 287 were included in the analysis of causes and antibody distribution. There were 183 cases of alloantibody-related difficult crossmatching (63. 76%), 54 cases related to inconsistency between ABO forward and reverse typing (18. 82%), 44 cases related to autoantibodies (15. 33%), and 6 cases related to interference from anti-CD38 monoclonal antibody drugs (2. 09%). Among the 183 alloantibody-related cases, 79 cases had only a single alloantibody detected, among which antibodies of the Rh blood group system accounted for 49. 37% (39/ 79). Among single alloantibodies, anti-E was detected most frequently, with 35 cases (44. 30%), followed by anti-M with 19 cases (24. 05%) and anti-Lea with 13 cases (16. 46%). A total of 109 cases were included in the exploratory subgroup analysis of transfusion efficacy, including 76 cases in the alloantibody-related difficult crossmatching group, 17 cases in the autoantibody-related or autoantibody combined with alloantibody-related difficult crossmatching group, and 16 cases in the ABO blood group identification abnormality-related difficult crossmatching group. The sex distribution and history of previous transfusion differed between cases included in and not included in this analysis. The Hb levels after transfusion in all three groups were higher than those before transfusion, and the differences were statistically significant (P<0. 05). The Hb increase per unit of red blood cells did not differ significantly among the three groups (P= 0. 086). Among 73 cases with paired total and indirect bilirubin data corresponding to the transfusion events, the comparison of changes in total bilirubin among the three groups showed no statistically significant difference (P= 0. 864), and the comparison of changes in indirect bilirubin among the three groups also showed no statistically significant difference (P= 0. 914). Conclusion Alloantibody-related factors were the main causes of difficult crossmatching in this study. Among single alloantibodies, Rh blood group system antibodies, especially anti-E, were relatively common. In the included exploratory subgroup, after individualized compatible transfusion based on the causes of difficult crossmatching, antibody specificities, and crossmatching results, Hb levels were higher after transfusion than before transfusion in all three groups. Within the scope of this study, the magnitude of bilirubin changes did not differ significantly among the different types of difficult crossmatching.

关键词

疑难配血 / 红细胞血型抗体 / 相容性输血 / 输血疗效

Key words

difficult crossmatching / red blood cell antibody / compatible transfusion / transfusion efficacy

引用本文

引用格式 ▾
官笑羽,康凯,李顺林,李族军,章容,吴迪,李玲. 疑难配血病例输血策略研究及输血疗效分析[J]. 中国输血杂志, 2026, 39(9): 1237-1245 DOI:10.13303/j.cjbt.issn.1004-549x.2026.09.011

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

ARTHUR C M, STOWELL S R. The development and consequences of red blood cell alloimmunization[J].Annu Rev Pathol, 2023, 18:537-564.

[2]

TORMEY C A, HENDRICKSON J E. Transfusion-related red blood cell alloantibodies: induction and consequences[J].Blood, 2019, 133(17):1821-1830.

[3]

红细胞血型抗原拓展匹配适用范围中国专家共识编写组. 红细胞血型抗原拓展匹配适用范围中国专家共识[J].临床输血与检验, 2024, 26(3):289-298.

[4]

EXPERT CONSENSUS DRAFTING GROUP OF RED BLOOD CELL ANTIGEN EXTENDED MATCHING RANGE. Chinese expert consensus on red blood cell antigen extended matching range[J].J Clin Transfus Lab Med, 2024, 26(3):289-298.

[5]

JOHNSON S T, PUCA K E. Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies[J].Hematology Am Soc Hematol Educ Program, 2022, 2022(1):96-104.

[6]

USMANI A, MORRIS G P, MURPHEY C. The increasing need for ABO blood group genotyping and quality assurance implications for laboratory implementation[J].Hum Immunol, 2024, 85(2):110766.

[7]

CHAPUY C I, NICHOLSON R T, AGUAD M D, et al. Resolving the daratumumab interference with blood compatibility testing[J].Transfusion, 2015, 55(6 Pt 2):1545-1554.

[8]

中华人民共和国国家卫生健康委员会. 临床用血技术规范(2025 年版)[S].北京:国家卫生健康委员会, 2025.

[9]

NATIONAL HEALTH COMMISSION OF THE PEOPLE'S REPUBLIC OF CHINA. Technical specification for clinical blood use (2025 edition)[S]. Beijing:National Health Commission of the People's Republic of China,2025.

[10]

中华人民共和国国家卫生健康委员会. 医疗机构临床用血管理办法(2019 年修订)[S].北京:国家卫生健康委员会, 2019.

[11]

NATIONAL HEALTH COMMISSION OF THE PEOPLE'S REPUBLIC OF CHINA. Administrative measures for clinical blood use in medical institutions (2019 revision)[S]. Beijing:National Health Commission of the People's Republic of China,2019.

[12]

欧阳旭, 周雪莹, 郑伟. 拟输血住院患者意外抗体的鉴定与红细胞输注疗效分析[J].临床血液学杂志, 2026, 39(6):505-509.

[13]

OUYANG X, ZHOU X Y, ZHENG W. Identification of irregular antibodies and analysis of efficacy of red blood cell transfusion in hospitalized patients with planed blood transfusion[J].J Clin Hematol, 2026, 39 (6): 505-509.

[14]

NAHENDRAN P, BUDIN S B, MOHD SAAT N Z, et al. Red cell alloimmunization in multitransfused hepatobiliary patients at hospital Selayang[J].Asian J Transfus Sci, 2024, 18(2):286-290.

[15]

ALMORISH M A W, AL-ABSI B, ELKHALIFA A M E, et al. Red blood cell alloimmunization in blood transfusion-dependent β-thalassemia major patients in Sana' a City-Yemen[J].Sci Rep, 2024, 14:1005.

[16]

ADANI S N, MOHD ASHARI N S, JOHAN M F, et al. Red blood cell alloimmunization in pregnancy:a review of the pathophysiology, prevalence, and risk factors[J].Cureus, 2024, 16(5):e60158.

[17]

AKINBOLAJI T J. When and why is red blood cell genotyping applicable in transfusion medicine: a systematic review of the literature[J].Immunohematology, 2024, 40(2):58-64.

[18]

WEMELSFELDER M L, VAN DE WEEM R H G, LUKEN J S, et al. Extensive red blood cell matching considering patient alloimmunization risk[J].Vox Sang, 2024, 119(4):368-376.

[19]

LEAL I, DOS SANTOS T D, GILLI S, et al. Effects of prophylactic red blood cell transfusion with extended antigen matching on alloimmunization in patients with sickle cell disease[J].Transfus Apher Sci, 2023, 62(6):103813.

[20]

庄金木, 黄文庆, 张云聪, 等. 抗原拓展匹配在自身免疫性溶血性贫血输血中的应用[J].中国输血杂志, 2026, 39(1):109-113.

[21]

ZHUANG J M, HUANG W Q, ZHANG Y C, et al. Application of extended antigen matching in transfusion for patients with autoimmune hemolytic anemia[J].Chin J Blood Transfusion, 2026, 39(1):109-113.

[22]

赵震, 马筱慧, 钟靖, 等. 温抗体型自身免疫性溶血性贫血输血有效性分析[J].临床血液学杂志, 2025, 38(2):109-112.

[23]

ZHAO Z, MA X H, ZHONG J, et al. Analysis of the effect of blood transfusion in patients with warm antibody type autoimmune hemolytic anemia[J].J Clin Hematol, 2025, 38(2):109-112.

[24]

MICHAEL H, SHAIJI P S, SREENATH S, et al. Safety and efficacy of least incompatible red cell units in autoimmune hemolytic anemia:a prospective analysis of hemoglobin increment and hemolysis after transfusion[J].Asian J Transfus Sci, 2025, 19(2):237-243.

[25]

VERSINO F, REVELLI N, VILLA S, et al. Transfusions in autoimmune hemolytic anemias: frequency and clinical significance of alloimmunization[J].J Intern Med, 2024, 295(3):369-374.

[26]

JALINK M, YAN M T S, COHN C S, et al. Systematic review for the serological testing for cold agglutinins:the BEST collaborative study[J].Transfusion, 2024, 64(7):1331-1349.

[27]

BARCELLINI W, FATTIZZO B. The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease[J].Expert Rev Hematol, 2024, 17(7):287-294.

基金资助

成都市科技局成果转化示范项目(2024-YF09-00052-SN)

成都市第三人民医院科研项目(2023PI10)

AI Summary AI Mindmap
PDF (1894KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉